Curtin University Homepage
  • Library
  • Help
    • Admin

    espace - Curtin’s institutional repository

    JavaScript is disabled for your browser. Some features of this site may not work without it.
    View Item 
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item

    Influence of local recurrence on survival in patients with rectal cancer

    196143_196143.pdf (738.9Kb)
    Access Status
    Open access
    Authors
    Platell, Cameron
    Spilsbury, Katrina
    Date
    2014
    Type
    Journal Article
    
    Metadata
    Show full item record
    Citation
    Platell, Cameron and Spilsbury, Katrina. 2014. Influence of local recurrence on survival in patients with rectal cancer. ANZ Journal of Surgery. 84 (1-2): pp. 85-90.
    Source Title
    ANZ Journal of Surgery
    DOI
    10.1111/ans.12214
    ISSN
    1445-2197
    Remarks

    This is the accepted version of the following article: Platell, Cameron and Spilsbury, Katrina. 2014. Influence of local recurrence on survival in patients with rectal cancer. ANZ Journal of Surgery. 84 (1-2): pp. 85-90, which has been published in final form at http://doi.org/10.1111/ans.12214

    URI
    http://hdl.handle.net/20.500.11937/16216
    Collection
    • Curtin Research Publications
    Abstract

    Background: Recent trials on rectal cancer have demonstrated significant improvements in local recurrence without improvements in overall survival. The aim of this paper was to define the influence of local recurrence on survival in a prospective series of patients who underwent R0 or R1 resections for rectal cancer. Methods: Patients presenting with rectal cancer from 1996 to 2012 were prospectively audited. The study included patients who underwent an R0 or R1 resection. Local recurrence was defined as cancer regrowth detected in the pelvis regardless of whether or not new metastases were found elsewhere. Kaplan–Meier curves, smoothed hazard functions and Cox models using both time since diagnosis and age as the time scale were used to define the influence of local recurrence on overall survival. Results: The study involved 483 patients, of mean age 66 years (standard deviation = 13) and a median follow-up of 5.2 years. The results at 5 years were overall survival 71% (95% confidence interval (CI) 66–75), local recurrence 7% (95% CI 5–10) and distant recurrence 18% (95% CI 14–22). Patients diagnosed with local recurrence died faster than patients diagnosed with either distant recurrence or no recurrence, and this was particularly obvious for younger patients (local hazard ratio (HR) 54, 95% CI 12–253 and distant HR19, 95% CI 4–80). Local recurrence that developed early following surgery also had worse survival outcomes. Conclusions: Within this cohort of rectal cancer patients, the early development of local recurrence was the single most important indicator of a reduced survival, and carried a worse prognosis than the development of distant metastases alone.

    Related items

    Showing items related by title, author, creator and subject.

    • A retrospective study investigating the rate of HER2 discordance between primary breast carcinoma and locoregional or metastatic disease
      Chan, Arlene; Morey, A.; Brown, B.; Hastrich, D.; Willsher, P.; Ingram, D. (2012)
      Background: Overall survival of HER2 positive metastatic breast cancer patients has been significantly improved with inclusion of trastuzumab to chemotherapy. Several studies have demonstrated discordant HER2 status in ...
    • Tumour-infiltrating regulatory T cell density before neoadjuvant chemoradiotherapy for rectal cancer does not predict treatment response
      McCoy, M.; Hemmings, C.; Anyaegbu, C.; Austin, S.; Lee-Pullen, T.; Miller, T.; Bulsara, M.; Zeps, Nikolajs; Nowak, A.; Lake, R.; Platell, C. (2017)
      Neoadjuvant (preoperative) chemoradiotherapy (CRT) decreases the risk of rectal cancer recurrence and reduces tumour volume prior to surgery. However, response to CRT varies considerably between individuals and factors ...
    • Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
      Martin, M.; Holmes, F.; Ejlertsen, B.; Delaloge, S.; Moy, B.; Iwata, H.; von Minckwitz, G.; Chia, S.; Mansi, J.; Barrios, C.; Gnant, M.; Tomaševic, Z.; Denduluri, N.; Šeparovic, R.; Gokmen, E.; Bashford, A.; Ruiz Borrego, M.; Kim, S.; Jakobsen, E.; Ciceniene, A.; Inoue, K.; Overkamp, F.; Heijns, J.; Armstrong, A.; Link, J.; Joy, A.; Bryce, R.; Wong, A.; Moran, S.; Yao, B.; Xu, F.; Auerbach, A.; Buyse, M.; Chan, Arlene; ExteNET Study Group (2017)
      Background: ExteNET showed that 1 year of neratinib, an irreversible pan-HER tyrosine kinase inhibitor, significantly improves 2-year invasive disease-free survival after trastuzumab-based adjuvant therapy in women with ...
    Advanced search

    Browse

    Communities & CollectionsIssue DateAuthorTitleSubjectDocument TypeThis CollectionIssue DateAuthorTitleSubjectDocument Type

    My Account

    Admin

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Follow Curtin

    • 
    • 
    • 
    • 
    • 

    CRICOS Provider Code: 00301JABN: 99 143 842 569TEQSA: PRV12158

    Copyright | Disclaimer | Privacy statement | Accessibility

    Curtin would like to pay respect to the Aboriginal and Torres Strait Islander members of our community by acknowledging the traditional owners of the land on which the Perth campus is located, the Whadjuk people of the Nyungar Nation; and on our Kalgoorlie campus, the Wongutha people of the North-Eastern Goldfields.